AACR 2026: Early clinical activity from the phase 1 evaluation of CID-078, a novel cyclin A/B RxL inhibitor, in patients with advanced solid tumors

Circle Pharma Inc. published this content on April 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 19, 2026 at 23:03 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]